Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia

Dipti Talaulikar*, Cécile Tomowiak, Elise Toussaint, Pierre Morel, Prashant Kapoor, Jorge J. Castillo, Alain Delmer, Eric Durot

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    5 Citations (Scopus)

    Abstract

    KEY POINTS Histologic transformation should be suspected in patients with WM that develop constitutional symptoms, rapidly progressive lymphadenopathy, extranodal involvement, sudden rise in LDH levels, and/or decreased serum IgM levels. Tissue biopsy is mandatory to diagnose histologic transformation and may be directed by clinical or radiologic features (ie, by site of rapidly enlarging lymph nodes, or by site of increased avidity on 18FFDG-PET/CT). Histologic diagnosis is required to confirm transformation to high-grade lymphoma. Most transformation events are caused by DLBCL variants, but rarely other aggressive lym phomas may occur. Treatment with intermediate-dose chemoimmunotherapy, such as R-CHOP, is the preferred option. CNS prophylaxis with HD-MTX should be considered if feasible and consolidation with autologous SCT should be discussed in fit patients responding to chemoimmunotherapy. If available, enrollment in clinical trials should be recommended.
    Original languageEnglish
    Pages (from-to)787-799
    Number of pages13
    JournalHematology/Oncology Clinics of North America
    Volume37
    Issue number4
    DOIs
    Publication statusPublished - Aug 2023

    Fingerprint

    Dive into the research topics of 'Evaluation and Management of Disease Transformation in Waldenström Macroglobulinemia'. Together they form a unique fingerprint.

    Cite this